New Blood Tests and Biomarkers for Early Detection this week: The Alzheimer’s disease clinical landscape is consolidating around biomarker-confirmed diagnosis and modestly; and In a 2026 update, Dr.
Anavex Life Sciences presented new long-term data for its investigational oral therapy blarcamesine (Anavex 2-73) at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases.